Stocks
Lilly’s Retatrutide Shows Broad Benefits in Obesity Trials
Eli Lilly's experimental obesity drug retatrutide delivered positive late-stage trial results, showing substantial weight loss and improvements in type 2 diabetes, knee...
#eli lilly 2 articles
Stocks
Eli Lilly Nears $2B-Plus Kelonia Deal for Cancer Pipeline
Eli Lilly is in advanced talks to acquire Kelonia Therapeutics for over $2 billion, aiming to expand its cancer pipeline, The Wall...